Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting Seite 1

31.10.2023 - Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters ... Seite 1

Related Keywords

California , United States , San Diego , Randi Isaacs , Company Or Werewolf Nasdaq , Werewolf Therapeutics Inc , Society For Immunotherapy Of Cancer , Annual Meeting , Chief Medical Officer , Werewolf Therapeutics Chart , Erewolf Therapeutics Kurs , Erewolf Therapeutics Aktie ,